Sonoma Pharmaceuticals, INC. (SNOA) — SEC Filings

Overview

Sonoma Pharmaceuticals, INC. (SNOA) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a EFFECT filed on Apr 24, 2026: Sonoma Pharmaceuticals, Inc. filed an EFFECT form on April 24, 2026, indicating the effectiveness of a registration statement. The filing, with SEC Accession No. 9999999995-26-001319, relates to Act 33 and File No. 333-295171. The company's business address is 5445 Conestoga Court, Suite 150, Boulde

Sentiment Summary

Across 37 filings, the sentiment breakdown is: 4 bearish, 33 neutral. The dominant filing sentiment for Sonoma Pharmaceuticals, INC. is neutral.

Filing Type Overview

Sonoma Pharmaceuticals, INC. (SNOA) has filed 1 EFFECT, 24 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 2 DEFA14A with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (37)

• Sonoma Pharmaceuticals Filing Effectiveness Notice — EFFECT · Apr 24, 2026 Risk: low
  Sonoma Pharmaceuticals, Inc. filed an EFFECT form on April 24, 2026, indicating the effectiveness of a registration statement. The filing, with SEC Accession No
• Sonoma Pharmaceuticals Enters Manufacturing Agreement — 8-K · Apr 9, 2026 Risk: medium
  On April 8, 2026, Sonoma Pharmaceuticals, Inc. entered into a material definitive agreement, specifically a Manufacturing and Supply Agreement. The filing detai
• Sonoma Pharma's Revenue Jumps, But Cash Drains Amidst Mounting Losses — 10-Q · Nov 4, 2025 Risk: high
  Sonoma Pharmaceuticals, Inc. (SNOA) reported a net loss of $534,000 for the three months ended September 30, 2025, an improvement from a net loss of $610,000 in
• Sonoma Pharmaceuticals Reports Officer and Director Changes — 8-K · Oct 23, 2025 Risk: low
  Sonoma Pharmaceuticals, Inc. filed an 8-K on October 23, 2025, reporting changes effective October 18, 2025. The filing covers the departure of directors or cer
• Sonoma Pharmaceuticals Reports Director/Officer Changes & Financials — 8-K · Oct 9, 2025 Risk: medium
  Sonoma Pharmaceuticals, Inc. filed an 8-K on October 9, 2025, reporting changes in its board of directors and officers, along with updates to compensatory arran
• Sonoma Pharmaceuticals Files 8-K, Confirms Nasdaq Listing — 8-K · Sep 29, 2025 Risk: low
  Sonoma Pharmaceuticals, Inc. filed an 8-K on September 29, 2025, reporting its status as an emerging growth company. The filing indicates that the company's com
• Sonoma Pharmaceuticals Files 8-K — 8-K · Sep 26, 2025 Risk: low
  Sonoma Pharmaceuticals, Inc. filed an 8-K on September 26, 2025, reporting the entry into a material definitive agreement and the filing of financial statements
• Sonoma Pharmaceuticals Files 8-K on Shareholder Votes — 8-K · Aug 29, 2025 Risk: low
  Sonoma Pharmaceuticals, Inc. filed an 8-K on August 29, 2025, reporting on matters submitted to a vote of security holders as of August 27, 2025. The filing det
• Sonoma Pharma's Q1 Revenue Dips 17%, Net Loss Widens — 10-Q · Aug 7, 2025 Risk: high
  Sonoma Pharmaceuticals, Inc. reported a significant decline in revenue for the three months ended June 30, 2025, dropping to $3.5 million from $4.2 million in t
• Sonoma Pharma Details Executive Pay, Governance Ahead of Shareholder Vote — DEF 14A · Jul 11, 2025 Risk: medium
  Sonoma Pharmaceuticals, Inc. (SNOA) filed its DEF 14A, indicating a focus on executive compensation and corporate governance for the fiscal year ending March 31
• Sonoma Pharma's Sales Plunge 20% as Losses Mount to $10.5M — 10-K · Jun 17, 2025 Risk: high
  Sonoma Pharmaceuticals, Inc. reported a significant decline in revenue for the fiscal year ended March 31, 2025, with net sales decreasing by 20.3% to $18.5 mil
• 8-K Filing — 8-K · Apr 28, 2025
• 8-K Filing — 8-K · Apr 7, 2025
• Sonoma Pharmaceuticals Enters Material Definitive Agreement — 8-K · Mar 25, 2025 Risk: medium
  Sonoma Pharmaceuticals, Inc. entered into a Material Definitive Agreement on March 21, 2025. The filing also includes financial statements and exhibits related
• Sonoma Pharmaceuticals Files Q3 2025 10-Q — 10-Q · Feb 5, 2025 Risk: medium
  Sonoma Pharmaceuticals, Inc. filed its 10-Q for the period ending December 31, 2024. The company, formerly known as Oculus Innovative Sciences, Inc., is in the
• Sonoma Pharmaceuticals Enters Material Definitive Agreement — 8-K · Jan 30, 2025 Risk: medium
  Sonoma Pharmaceuticals, Inc. announced on January 29, 2025, that it entered into a Material Definitive Agreement. The company, formerly known as Oculus Innovati
• Sonoma Pharmaceuticals Reports Director and Officer Changes — 8-K · Jan 3, 2025 Risk: medium
  Sonoma Pharmaceuticals, Inc. filed an 8-K on January 3, 2025, reporting changes effective January 2, 2025. The filing covers the departure and election of direc
• Sonoma Pharmaceuticals Terminates Material Agreement — 8-K · Nov 21, 2024 Risk: medium
  Sonoma Pharmaceuticals, Inc. announced on November 21, 2024, the termination of a material definitive agreement. The filing does not specify the counterparty or
• Sonoma Pharmaceuticals Files Q2 FY25 10-Q — 10-Q · Nov 7, 2024 Risk: medium
  Sonoma Pharmaceuticals, Inc. filed its 10-Q for the period ending September 30, 2024. The company, formerly Oculus Innovative Sciences, Inc., reported financial
• Sonoma Pharmaceuticals Enters Material Definitive Agreement — 8-K · Oct 22, 2024 Risk: medium
  Sonoma Pharmaceuticals, Inc. announced on October 17, 2024, that it entered into a material definitive agreement. The company, formerly known as Oculus Innovati
• Sonoma Pharmaceuticals Files 8-K — 8-K · Sep 20, 2024 Risk: low
  Sonoma Pharmaceuticals, Inc. filed an 8-K on September 20, 2024, reporting on other events and financial statements. The company, formerly known as Oculus Innov
• Sonoma Pharmaceuticals Files 8-K with Key Corporate Updates — 8-K · Aug 28, 2024 Risk: low
  Sonoma Pharmaceuticals, Inc. filed an 8-K on August 23, 2024, reporting on several key events. These include amendments to its Articles of Incorporation or Byla
• Sonoma Pharmaceuticals Files 8-K — 8-K · Aug 23, 2024 Risk: low
  Sonoma Pharmaceuticals, Inc. filed an 8-K on August 22, 2024, reporting other events and financial statements. The company, formerly known as Oculus Innovative
• Sonoma Pharmaceuticals Files 8-K — 8-K · Aug 21, 2024 Risk: low
  Sonoma Pharmaceuticals, Inc. filed an 8-K on August 21, 2024, reporting a material definitive agreement and financial statements. The filing date indicates even
• Sonoma Pharma Annual Meeting Adjourned to Aug 23 — DEFA14A · Aug 15, 2024 Risk: medium
  Sonoma Pharmaceuticals, Inc. has adjourned its Annual Meeting of Stockholders to August 23, 2024, at 11 a.m. local time. The meeting was moved from its original
• Sonoma Pharmaceuticals Files Q1 2025 10-Q — 10-Q · Aug 8, 2024 Risk: low
  Sonoma Pharmaceuticals, Inc. filed its 10-Q for the period ending June 30, 2024. The filing covers the first quarter of their fiscal year 2025. The company prev
• Sonoma Pharma Seeks Stockholder Votes for Annual Meeting — DEFA14A · Jul 24, 2024 Risk: low
  Sonoma Pharmaceuticals, Inc. is soliciting proxies for its annual meeting of stockholders scheduled for August 14, 2024. The company is urging stockholders who
• Sonoma Pharmaceuticals Files Definitive Proxy Statement — DEF 14A · Jul 1, 2024 Risk: low
  Sonoma Pharmaceuticals, Inc. filed a Definitive Proxy Statement (DEF 14A) on July 1, 2024, for the fiscal year ending March 31, 2024. The company, formerly know
• Sonoma Pharmaceuticals Files 8-K — 8-K · Jun 27, 2024 Risk: low
  Sonoma Pharmaceuticals, Inc. filed an 8-K on June 27, 2024, reporting other events and financial statements. The company, formerly known as Oculus Innovative Sc
• Sonoma Pharmaceuticals Files 2024 10-K — 10-K · Jun 17, 2024 Risk: medium
  Sonoma Pharmaceuticals, Inc. filed its 10-K for the fiscal year ending March 31, 2024. The company, formerly Oculus Innovative Sciences, Inc., is engaged in the
• Sonoma Pharmaceuticals Files 8-K — 8-K · Apr 9, 2024 Risk: low
  Sonoma Pharmaceuticals, Inc. filed an 8-K on April 9, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly
• Sonoma Pharmaceuticals Files 8-K — 8-K · Apr 2, 2024 Risk: low
  Sonoma Pharmaceuticals, Inc. filed an 8-K on April 2, 2024, reporting on Regulation FD disclosures and financial statements/exhibits. The company, formerly Ocul
• Sonoma Pharmaceuticals Faces Delisting Notice — 8-K · Mar 22, 2024 Risk: high
  Sonoma Pharmaceuticals, Inc. filed an 8-K on March 22, 2024, to report a notice of delisting or failure to satisfy a continued listing rule. The company was for
• Sonoma Pharmaceuticals Enters Material Definitive Agreement — 8-K · Mar 8, 2024 Risk: medium
  Sonoma Pharmaceuticals, Inc. announced on March 8, 2024, that it entered into a Material Definitive Agreement. The filing does not provide specific details abou
• Sonoma Pharmaceuticals, Inc. Files 10-Q for Period Ending December 31, 2023 — 10-Q · Feb 8, 2024 Risk:
  Sonoma Pharmaceuticals, Inc. (SNOA) filed a Quarterly Report (10-Q) with the SEC on February 8, 2024. Sonoma Pharmaceuticals, Inc. filed a 10-Q for the period e
• Sonoma Pharma Confirms Nasdaq Listing for SNOA Common Stock — 8-K · Jan 10, 2024
  Sonoma Pharmaceuticals, Inc. filed an 8-K on January 10, 2024, to disclose that its Common Stock, trading under the symbol SNOA, is registered on The Nasdaq Sto
• Sonoma Pharma Enters Material Definitive Agreement on Jan 5 — 8-K · Jan 9, 2024
  Sonoma Pharmaceuticals, Inc. filed an 8-K on January 9, 2024, reporting a material definitive agreement entered into on January 5, 2024. This filing indicates a

Risk Profile

Risk Assessment: Of SNOA's 32 recent filings, 4 were flagged as high-risk, 13 as medium-risk, and 15 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Sonoma Pharmaceuticals, INC.'s most recent 10-Q filing (Nov 4, 2025):

• Revenue: $9.619M
• Net Income: -$1.775M
• EPS: N/A
• Debt-to-Equity: 2.66
• Cash Position: $3.035M
• Operating Margin: -14.9%
• Total Assets: $13.856M
• Total Debt: $10.069M

Key Executives

• Boulder, CO

Industry Context

Sonoma Pharmaceuticals operates in the pharmaceutical sector, which is characterized by high R&D costs, lengthy development cycles, and significant regulatory hurdles. The industry is competitive, with companies striving for innovation in drug discovery and commercialization. Trends include a focus on specialized therapeutics and increasing adoption of advanced manufacturing technologies.

Top Tags

financials (7) · material-agreement (6) · corporate-governance (6) · Pharmaceuticals (4) · 10-Q (4) · Net Loss (3) · Medical Devices (3) · corporate-event (3) · management-change (2) · material-definitive-agreement (2)

Executive Compensation

From the most recent DEF 14A filing (Jul 11, 2025):

• Not Specified — Not Specified: $0

Key Numbers

• Filing Acceptance Date: 2026-04-24 — Date the EFFECT filing was accepted by the SEC.
• Effectiveness Date: 2026-04-23 — The date the registration statement became effective.
• Revenue for Q3 2025: $5.604M — Increased from $3.579M in Q3 2024, a 56.5% increase.
• Revenue for six months ended Sept 30, 2025: $9.619M — Increased from $6.970M in the prior year, a 38% increase.
• Net loss for Q3 2025: $534K — Improved from a $610K net loss in Q3 2024.
• Net loss for six months ended Sept 30, 2025: $1.775M — Slightly higher than $1.753M in the prior year.
• Cash and cash equivalents at Sept 30, 2025: $3.035M — Decreased from $5.374M at March 31, 2025.
• Net cash used in operating activities for six months ended Sept 30, 2025: $2.650M — Increased significantly from $558K in the prior year.
• Accumulated deficit at Sept 30, 2025: $199.581M — Increased from $197.806M at March 31, 2025.
• Shares outstanding as of Nov 3, 2025: 1,701,076 — Reflects the impact of the August 29, 2024 reverse stock split.
• Q1 2025 Revenue: $3.5M — 16.7% decrease from Q1 2024
• Q1 2024 Revenue: $4.2M — baseline for revenue comparison
• Q1 2025 Net Loss: $2.1M — widened from Q1 2024
• Q1 2024 Net Loss: $1.8M — baseline for net loss comparison
• Revenue Change: -16.7% — percentage decrease year-over-year

Related Companies

SONM

Frequently Asked Questions